Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, is presenting at today’s Emerging Growth Investor Conference. The conference has built a reputation for being an effective way for publicly traded companies to present and communicate new products and services as well as other major announcements to thousands of individual and institutional investors and investment advisors and analysts. PBI president and CEO Richard T. Schumacher spoke at 9 a.m. ET; the focus of his presentation was on the much-anticipated commercial launch of the company’s Ultra Shear Technology(TM) (“UST”) nanoemulsification platform. Throughout the past few months, Pressure BioSciences has entered three agreements covering the production, distribution, commercial roll-out and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use; the company also has entered a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with more than $500 million in QVC sales. “All four contracts are based on the use of the UST platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics,” the company stated in the press release. “Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, astaxanthin, curcumin, retinol, prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The company plans to close on a minimum of six additional contracts over the remaining months of FY 2022, further adding to 2023 revenue.”
To view the full press release, visit https://ibn.fm/EDbRV
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating, or pressure cycling technology (“PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged for the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
